Illumination unit, electrodeless low-pressure discharge lamp, and coil suitable for use therein

An illumination unit according to the invention comprises an electrodeless low-pressure discharge lamp (20) and a supply device (50). The lamp has a discharge vessel (30) which encloses in a gastight manner a discharge space (31) which is provided with an ionizable filling. The lamp (20) further has a coil (40) provided with a winding (42) around a sintered core (41) of polycrystalline ferrite material, which winding (42) is connected to the supply device (50). The coil (40) is capable of inducing a high-frequency magnetic field which maintains a discharge in the discharge space (31). The losses in the core (41), when measured at room temperature in a magnetic field with a frequency of 3 MHz and a magnetic flux density of 10 mT, amount to at most 150 mW/cm<3>. This has the advantage that the lamp (20) ignites comparatively quickly and loads the supply device (50) comparatively weakly during ignition. The supply device (50) as a result can have a comparatively long useful life

Illumination control

Controlling a lighting system, which comprises a controller (2, 10), lighting units (6), and a sensing device. Each lighting unit comprises a lighting source (12) and a modulated light source (14). A single light source may be used to function as both the lighting source and the modulated light source. Each modulated light source emits uniquely modulated light. A radiation pattern of each modulated light source coincides substantially with a radiation pattern of a lighting source of the same lighting unit. The sensing device is suitable to sense modulated light in a viewing area. Lighting units from which the sensing device senses modulated light are identified from the modulation of that modulated light. The sensing device measures the intensity of the modulated light from the identified lighting unit. The lighting sources are controlled dependent on control data which comprises measuring values of measured light intensities

Artsen en apothekers miskennen vaak een door ACE-remmers geïnduceerde prikkelhoest, wat de therapietrouw verlaagt

OBJECTIVE: A common side-effect of angiotensin-converting enzyme inhibitors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recognise a dry cough to be ACEi-related may attempt to treat it with antitussives, instead of recommended ACEi substitution. The aim of this study was to quantify such prescription behaviour, as well as its influence on therapy compliance. DESIGN AND METHODS: Drug dispensing data were retrieved from the IADB.nl database in The Netherlands. A prescription sequence symmetry analysis was used to determine whether antitussive agents were prescribed more often following ACEi initiation than the other way around. Therapy compliance in both groups was assessed using the proportion of days covered (PDC) method; patients with a PDC ≥ 80% were considered compliant. RESULTS: 1601 patients were incident users of both ACEi and antitussives within a half-year time span. There was a significant excess of patients prescribed antitussive agents after ACEi initiation (1075 versus 526), yielding a sequence ratio of 2.0 (95% confidence interval 1.8-2.3). Therapy compliance in patients receiving antitussives after ACEi initiation was 58%, significantly lower than therapy compliance in control patients, which was 77% (

Misdiagnosis and mistreatment of ACE-inhibitor-induced cough occurs frequently and decreases therapy compliance

OBJECTIVE: A common side-effect of angiotensin-converting enzyme inhibitors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recognise a dry cough to be ACEi-related may attempt to treat it with antitussives, instead of recommended ACEi substitution. The aim of this study was to quantify such prescription behaviour, as well as its influence on therapy compliance. DESIGN AND METHODS: Drug dispensing data were retrieved from the IADB.nl database in The Netherlands. A prescription sequence symmetry analysis was used to determine whether antitussive agents were prescribed more often following ACEi initiation than the other way around. Therapy compliance in both groups was assessed using the proportion of days covered (PDC) method; patients with a PDC ≥ 80% were considered compliant. RESULTS: 1601 patients were incident users of both ACEi and antitussives within a half-year time span. There was a significant excess of patients prescribed antitussive agents after ACEi initiation (1075 versus 526), yielding a sequence ratio of 2.0 (95% confidence interval 1.8-2.3). Therapy compliance in patients receiving antitussives after ACEi initiation was 58%, significantly lower than therapy compliance in control patients, which was 77% (